- Home
- IMRX vs ASRT Comparison
IMRX vs ASRT Comparison
Compare IMRX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- ASRT
- Stock Information
- Founded
- IMRX 2008
- ASRT 1995
- Country
- IMRX United States
- ASRT United States
- Employees
- IMRX N/A
- ASRT N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- ASRT Health Care
- Exchange
- IMRX Nasdaq
- ASRT Nasdaq
- Market Cap
- IMRX 62.7M
- ASRT 65.7M
- IPO Year
- IMRX 2021
- ASRT 1997
- Fundamental
- Price
- IMRX $1.27
- ASRT $0.61
- Analyst Decision
- IMRX Strong Buy
- ASRT Strong Buy
- Analyst Count
- IMRX 2
- ASRT 3
- Target Price
- IMRX $12.50
- ASRT $3.08
- AVG Volume (30 Days)
- IMRX 170.4K
- ASRT 480.8K
- Earning Date
- IMRX 05-06-2025
- ASRT 05-05-2025
- Dividend Yield
- IMRX N/A
- ASRT N/A
- EPS Growth
- IMRX N/A
- ASRT N/A
- EPS
- IMRX N/A
- ASRT N/A
- Revenue
- IMRX N/A
- ASRT $124,961,000.00
- Revenue This Year
- IMRX N/A
- ASRT N/A
- Revenue Next Year
- IMRX N/A
- ASRT $11.20
- P/E Ratio
- IMRX N/A
- ASRT N/A
- Revenue Growth
- IMRX N/A
- ASRT N/A
- 52 Week Low
- IMRX $1.00
- ASRT $0.51
- 52 Week High
- IMRX $3.83
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- IMRX 34.48
- ASRT 39.17
- Support Level
- IMRX $1.23
- ASRT $0.58
- Resistance Level
- IMRX $1.38
- ASRT $0.80
- Average True Range (ATR)
- IMRX 0.11
- ASRT 0.05
- MACD
- IMRX -0.01
- ASRT 0.00
- Stochastic Oscillator
- IMRX 26.42
- ASRT 34.48
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.